Cargando…
β-catenin-activated autocrine PDGF/Src signaling is a therapeutic target in pancreatic cancer
K-ras mutation and p53 loss are the most prevalent genetic alterations in pancreatic cancer. In addition to these two alterations, pancreatic tumors frequently contain a third genetic defect. Mutations in the WNT/ß-catenin signaling molecules occur in 15-20% of pancreatic cancer patients and co-exis...
Autores principales: | Kuo, Tzu-Lei, Cheng, Kuang-Hung, Shan, Yan-Shen, Chen, Li-Tzong, Hung, Wen-Chun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376185/ https://www.ncbi.nlm.nih.gov/pubmed/30809277 http://dx.doi.org/10.7150/thno.28201 |
Ejemplares similares
-
Autocrine PDGF stimulation in malignancies
por: Heldin, Carl-Henrik
Publicado: (2012) -
Autocrine DUSP28 signaling mediates pancreatic cancer malignancy via regulation of PDGF-A
por: Lee, Jungwhoi, et al.
Publicado: (2017) -
WNT7B mediates autocrine Wnt/β-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma
por: Arensman, Michael D., et al.
Publicado: (2013) -
Deciphering The Potential Role of Hox Genes in Pancreatic Cancer
por: Kuo, Tzu-Lei, et al.
Publicado: (2019) -
Inhibition of β-Catenin Activity Abolishes LKB1 Loss-Driven Pancreatic Cystadenoma in Mice
por: Hsieh, Mei-Jen, et al.
Publicado: (2021)